Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 (apalulizumab) + bevacizumab first-line in chemotherapy-ineligible advanced NSCLC
ChiCTR2600117468Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab + tuvonralimab in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoint: Objective response rate (ORR). Started Jan 2026; status: recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600117468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600117468.